Veronica Salais Michaus

Medical Oncologist 🦀/Digestive oncology specialist 🍏/ Translational medicine🧬💛 Mexican 🇲🇽

[Josette Staufert @Staufertjr]

Multidisciplinary collaboration drives better care for our patients 🧬🤝🏻🩺

It was a pleasure to participate in the congress of Asociación Mexicana de Urología Oncológica 🇲🇽

[Dr Rishabh Jain @DrRishabhOnco]

🚨 HCC treatment is no longer a simple BCLC flowchart. It’s now a branching decision tree of transplant, locoregional therapy, immunotherapy, and sequencing.

The new Pan-Asian adapted ESMO HCC guideline makes that clear. 🧵

🔹 BCLC 0/A
Not just resection vs ablation anymore.
OLT, SBRT, proton, HDR brachytherapy, and TARE all enter the discussion in selected patients.

🔹 BCLC B
No longer a pure “TACE bucket.”
Beyond DEB-TACE / lipiodol TACE, the guideline also opens the door to:
▪️ TARE / bland embolisation
▪️ TACE + ICI/anti-angiogenic therapy
▪️ TACE + lenvatinib when ICI-based therapy is not feasible

🔹 BCLC C
First-line treatment now splits by ICI suitability.
If suitable: atezo-bev / durva-treme lead the pathway.
If not: lenvatinib or sorafenib remain the backbone.

🔹 Later lines
Treatment is now a sequencing problem, not a single-drug problem:
regorafenib, cabozantinib, sorafenib/lenvatinib, ramucirumab for AFP ≥400

Take-home

HCC management is now less about memorising one regimen for each BCLC stage and more about matching:
▪️ tumour stage
▪️ liver function / portal hypertension
▪️ transplant eligibility
▪️ ICI suitability
▪️ post-progression sequencing

That is the real shift in this guideline.

@myESMO @ESMO_Open @oncoalert @AASLDtweets @ILCAnews

#HCC #LiverCancer #Oncology #MedTwitter

[Erman Akkus @Erman_Akkus]

💊Cancer pain management
NCCN guideline summary

#cancer #oncology #MedX #pain

[Dr Sophia Wong @sophiawongyn]

Massive milestone for the first CAR-T in solid cancer. However a 3.25m PFS. Is the tox worth it? Durability is still key for #CellTherapy.

#CART

[Erman Akkus @Erman_Akkus]

🏥T4, MRF, CRM in rectal cancer for medical oncologists

✅All related but different concepts
➡️T4b but MRF- (e.g. upper third tm)
➡️MRF by MRI, CRM by pathological
➡️MRF- but CRM+ (e.g. technically hard surgery)

PS: prepared by AI. Surgeon, pathologist, radiologist colleagues may correct if wrong

#cancer #oncology #MedX #rectal #GI @OncoAlert

[Arndt Vogel @ArndtVogel]

Adjuvant aspirin for stage III CRC after curative resection: Primary analysis of the double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C)
#ASCO26
👉well tolerated, but no significant benefit in unselected pts in stage III
👉biomarker analysis ongoing
@myesmo @ASCO

[Arndt Vogel @ArndtVogel]

Informing optimal duration of adjuvant chemotherapy in resected stage I-IV CRC based on early ctDNA dynamics
#ASCO26
👉ctDNA dynamics @ 3mo highly prognostic
👉pts with detectable ctDNA may benefit from longer CTx
🧐Supports ctDNA guided adj. treatment
@myesmo @ASCO

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[OncoDaily GI @OncoDailyGI]

Fight CRC Opens Applications for Research Advocacy Training Program – Fight Colorectal Cancer

@FightCRC

https://t.co/d5F0FotpJi

[Marcelo Garrido @DrGarridoOncoGI]

Columna de opinión | Chile no puede perder terreno en investigación clínica - Portal Red Salud https://t.co/FM7kjN2qXg

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

This is a good example of a useless meta-analysis. Not everything needs a meta-analysis. This study combines retrospective studies with the now “statement of concern” only RCT of timing of immunotherapy and concludes that earlier time of day administration improves survival 🤦‍♂️
GIGO.
I wrote about these pointless meta analyses in @TheLancetOncol 8 years ago-https://t.co/UKBW0pX5s9

[RioOncology @RIO_Oncology]

Ultimo post en 🇪🇸 Cómo leer un ensayo clínico para oncólogos ocupados, basado en el paper de @oncology_bg

✅El comparador era válido?
✅Quién lo paga?
✅SG o SLE?
✅Crossover?
✅El beneficio importa?
✅Se parecen a mis pacientes?
✅Qué toxicidad?
+ en:
https://t.co/XMQaKopxR0

[OncoDaily GI @OncoDailyGI]

Enriching Exchange of Latin American and Global Oncology Perspectives - Veronica Salais Michaus (@MichausSalais)

@myESMO

https://t.co/TRl48lMsnG

#OncoDaily #Oncology #Cancer #Health #Medicine #MedX

[Veronica Salais Michaus @MichausSalais]

I had the privilege of participating in a biliopancreatic tumors preceptorship at Hospital Clínic de Barcelona ⁦@MacarullaTeresa⁩

I am deeply grateful to all the faculty and speakers for their generosity in sharing their knowledge and experience ⁦@hospitalclinic⁩

[Veronica Salais Michaus @MichausSalais]

@oncodaily @OncoDailyGI

[Veronica Salais Michaus @MichausSalais]

Grateful for the opportunity to present a clinical case at the ESMO Preceptorship in Gastroesophageal Cancer in Colombia🇨🇴 @Betzabe100 @myESMO

An enriching exchange of Latin American and global perspectives with inspiring colleagues, mentors, and friends.

[Diego Felipe Ballen @BallenDF]

New mCRC ESMO guidelines!
Triplet chemo + bevacizumab → SoC regardless of sidedness in mKRAS MSS/non-BRAF pts. TRIPLETE (+ EGFR) may also have a role in selected subgroups. Updated maintenance strategies too. Let’s review & discuss 👏🏻

[MV Chandrakanth @ChandrakanthMv]

MMR IHC Interpretation – Super Simple Quick Algorithm 🔥

Test the 4 proteins → All present? → pMMR (good)

One or more missing? → dMMR (needs attention)

Then follow the exact pattern of loss:

MLH1 & PMS2 lost (most common) → Check BRAF & MLH1 methylation

MSH2 & MSH6 lost → Likely Lynch
Only MSH6 or only PMS2 lost → Possible Lynch

Weird single losses (MSH2 alone or MLH1 alone) → Not possible, recheck!

Key rule: Always read MMR as pairs, not single markers!

(MLH1 protects PMS2 • MSH2 protects MSH6)

Saves time in daily practice. Save & share!

#MVOnco #Oncology #Pathology #MedEd

[OncoDaily GI @OncoDailyGI]

🇫🇷 French Intergroup Guidelines 2026: Gastric Cancer

Updated clinical practice guidelines provide a comprehensive framework for the management of gastric and gastroesophageal junction adenocarcinoma, covering diagnosis, staging, treatment strategies, and follow-up, with increasing integration of biomarker-driven approaches.

@MeherAbdelghani @MichelDucreux

📎 https://t.co/eNoPxTKLf6

#GastricCancer #GIOncology #Oncology #PrecisionOncology

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧪 NOM (W&W) in LARC
📊 Paradigm shift: surgery no longer mandatory in selected pts
🔹 cCR after TNT/immunotherapy → NOM feasible (~40%)
🔹 Organ preservation + QoL benefit
🔹 Requires strict selection + intensive follow-up
💥 De-escalation after upfront intensification

🔗 https://t.co/wVtDzGn2lx
@OncoAlert